<DOC>
	<DOCNO>NCT03076164</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability overall response rate trametinib give combination erlotinib patient Stage IV recurrent lung adenocarcinoma treat curative intent .</brief_summary>
	<brief_title>A Phase 1/2 Trial Trametinib Erlotinib Patients With EGFR-Mutant Lung Adenocarcinomas Acquired Resistance Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Pathologic evidence advance stage IV recurrent lung adenocarcinoma review MSKCC Somatic activate mutation EGFR Radiographic progression treatment erlotinib . Any number prior chemotherapy regimen permit . Measurable ( RECIST 1.1 ) indicator lesion previously irradiate KPS &gt; /= 70 % Age &gt; 18 year old Must undergone biopsy development acquire resistance erlotinib available archive tissue ( equivalent &gt; 10 unstained slide ) Left ventricular Ejection Fraction &gt; /= low limit normal ECHO MUGA Adequate organ function : AST , ALT &lt; /= 2.5 x ULN Total bilirubin &lt; /= 1.5 x ULN Albumin &gt; /=2.6g/dL Creatinine &lt; 1.5 x ULN OR calculate creatinine clearance &gt; /=50mL/min Absolute neutrophil count ( ANC ) &gt; /= 1,200 cells/mm3 Hemoglobin &gt; /=9.0 g/dL Platelets &gt; /=100,000/mm3 Patients symptomatic brain metastasis require escalate dos steroid Patients grade 2 great diarrhea prior study initiation despite maximal medical management due medication medical condition Crohn 's disease malabsorption Pregnant lactate woman Any type systemic therapy ( chemotherapy experimental drug ) within 2 week start treatment protocol except EGFR TKI Patients receive prior treatment MEK inhibitor Any major surgery extensive radiotherapy within 21 day start treatment protocol . A history clinically significant interstitial lung disease pneumonitis Clinically significant cardiac disease include unstable angina , acute myocardial infarction within 6 month Day 1 study administration , New York Heart Association Class III IV congestive heart failure , symptomatic uncontrolled Arrythmias , prolong correct QT interval &gt; 480msec , treatment refractory hypertension , presence cardiac defibrillator History central serous retinopathy retinal vein occlusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>erlotinib</keyword>
	<keyword>trametinib</keyword>
	<keyword>15-098</keyword>
</DOC>